AI as an independent second reader in detection of clinically relevant breast cancers within a population-based screening programme in the Netherlands: a retrospective cohort study
- PMID: 40816977
- DOI: 10.1016/j.landig.2025.100882
AI as an independent second reader in detection of clinically relevant breast cancers within a population-based screening programme in the Netherlands: a retrospective cohort study
Abstract
Background: Breast cancer screening programmes have shown to reduce mortality, but current methods face challenges such as limited mammographic sensitivity, limited resources, and variability in radiologist expertise. Artificial intelligence (AI) offers potential to improve screening accuracy and efficiency. This study simulated different screening scenarios, evaluating the performance of population-based breast cancer screening when using an AI system as a stand-alone reader or second reader.
Methods: In this retrospective cohort study, 42 236 consecutive 2D mammograms from 42 100 women attending the Dutch population-based breast cancer screening between Sept 1, 2016, and Aug 31, 2018 were processed by an AI-based cancer detection system (Transpara version 1.7.0, ScreenPoint Medical). Verified outcomes from the Netherlands Cancer Registry on screen-detected cancers, interval cancers, and later-in-future-detected breast cancers were available with 4-year follow-up. We compared sensitivity, specificity, and recall-rate between single human reading, double human reading, stand-alone AI reading, and combined single human reading with AI. Furthermore, we assessed potential differences in performance regarding breast density, tumour size, lymph-node positivity, and invasiveness between cancers identified by single human readers and AI alone.
Findings: After follow-up, 580 mammograms (579 woman) were labelled positive: 291 screen-detected cancers, 102 interval cancers, and 187 future breast cancers. Double human reading recalled 1244 mammograms (2·9%, 291 screen-detected cancers) and combined single human reading with AI recalled 2112 mammograms (5·0%, 282 screen-detected cancers, 29 interval cancers, 38 future breast cancers), improving the sensitivity by 8·4% (95% CI 5·7-11·2, p<0·0001). No significant difference in performance between combined single human reading with AI across density categories was found. AI-detected future breast cancers and interval cancers missed by human readers were more often invasive cancers (26·7%) or tumours larger than 20 mm in diameter (16·6%) by the time of eventual detection compared with the average screen-detected cancers.
Interpretation: Evaluating screening mammograms with one human reader and AI leads to increased breast cancer detection compared with double human reading, independent of breast density. However, an effective arbitration process is needed as the recall rate increases. AI-identified breast cancers that are missed by human readers seem larger and more often invasive by the time they are eventually detected, confirming the clinical relevance of these cases, recognisable by AI at an earlier stage.
Funding: MARBLE.
Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests NJ: employee of ScreenPoint Medical. JK: employee and shareholder of Screenpoint Medical. JT: shareholder of Ellogon.ai; has a patent pending on Cone Beam Computed Tomography reconstruction. MB: grants or grants pending with Hologic, Sectra Benelux, Volpara Solutions, Lunit, iCAD, and ScreenPoint Medical; and received payment for lectures from Hologic and Siemens Healthcare. NK: co-founder, consultant (in the role of CSO), and Board Member for ScreenPoint Medical; holds stock or stock options in ScreenPoint Medical; shareholder of QView Medical and former shareholder of Volpara. RMM: member of the executive board and Chair of the scientific committee EUSOBI, Chair of the Dutch College of Breast Imaging, member of the Research Committee ESR, an advisory editorial board member of European Radiology, and an associate editor at Radiology; has grants or grants pending with European Research Council, Horizon Europe, The Netherlands Research Council, The Dutch Cancer Society, Health Holland, Siemens Healthineers, Bayer Healthcare, Beckton & Dickinson, Screenpoint Medical, Lunit, PA Imaging, and Koning; royalties or licenses with Elsevier; consulting fees with Screenpoint Medical, Beckton & Dickinson, Siemens Healthineers, and Bayer Healthcare; and participation on a Data Safety Monitoring Board or Advisory Board with the SMALL study. IS: grants or grants pending with Sectra Benelux, Siemens Healthineers, Canon Medical, Volpara Solutions, and Screenpoint Medical; honoraria from Canon Medical; support for attending meetings or travel from Canon Medical; scientific advisory board member for Koning Corp; leadership or fiduciary role for AAPM Imaging Physics Committee; stock or stock options for Koning Corp; and receipt of equipment, materials, drugs, medical writing, or gifts or other services from Lunit, Hologic, iCAD, ScreenPoint Medical, and Volpara Solutions. Data were handled and controlled at all times by the other non-ScreenPoint employee authors. All other authors report no competing interests.
Comment in
-
Enhancing Breast Cancer Screening by Human-Artificial Intelligence Collaboration: The Clinical Promise and Challenges.AJR Am J Roentgenol. 2025 Oct 15. doi: 10.2214/AJR.25.34018. Online ahead of print. AJR Am J Roentgenol. 2025. PMID: 41090648
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
